| Indication | Program / Regulatory Pathway | Discovery | Pre-clinical | Phase I | Phase II | Phase III | NDA | FDA Approval |
| Opioid Overdose | NARCAN® Nasal Spray | |||||||
| Opioid Overdose | OPNT003 Nalmefene Nasal Spray | |||||||
| Alcohol Use Disorder | OPNT002 Opioid Antagonist Nasal Spray | |||||||
| Acute Cannabinoid Overdose | OPNT004 Drinabant (CB-1 Antagonist) | |||||||
| Opioid Use Disorder | OPNT005 Heroin Vaccine: hapten + liposome adjuvant | |||||||
